Clinical Trial Detail

NCT ID NCT03725059
Title Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements yes
Sponsors Merck Sharp & Dohme Corp.
Indications

invasive ductal carcinoma

Therapies

Cyclophosphamide + Doxorubicin + Paclitaxel + Pembrolizumab

Cyclophosphamide + Epirubicin + Paclitaxel

Pembrolizumab

Cyclophosphamide + Doxorubicin + Paclitaxel

Cyclophosphamide + Epirubicin + Paclitaxel + Pembrolizumab

Age Groups: adult senior

Additional content available in CKB BOOST